[Skip to Content]
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
June 2001

Anti–Tumor Necrosis Factor α Therapy in Psoriatic Arthritis and Psoriasis

Arch Dermatol. 2001;137(6):784-785. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-137-6-deb10000

Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial

Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ

Lancet. 2000;356:385-390

Tumor necrosis factor α (TNF-α) may play an important role in the pathogenesis of psoriasis and other inflammatory skin disorders.13 Recently, 2 types of TNF blockers have become available for clinical use: a soluble receptor (etanercept) and an anti–TNF-α monoclonal antibody (infliximab). Etanercept is a genetically engineered fusion protein consisting of 2 identical chains of the recombinant extracellular human TNF-receptor p75 monomer fused with the Fc domain of human IgG1, and is given subcutaneously twice a week.4 Infliximab has the variable region of a murine antibody grafted to the constant region of a human antibody, and is administered intravenously every 4 or 8 weeks.5

First Page Preview View Large
First page PDF preview
First page PDF preview